All In Biotech

Drug Trial Radar · NCT03625622

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Apr 1, 2019

Primary completion

Dec 21, 2020

Study completion Jun 28, 2021

Sponsor

Lead sponsor
AriBio Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks. An optional 26 week extension phase will be available to participants who successfully complete the original phase of the study.

Conditions

  • Mild to Moderate Alzheimer's Disease

Interventions

  • AR1001 10mgDrug

    AR1001 Active Oral Tablet 10mg

  • PlaceboDrug

    Placebo Oral Tablet

  • AR1001 30mgDrug

    AR1001 Active Oral Tablet 30mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)Time frame: Baseline to Week 26
  2. Change From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)Time frame: Baseline to Week 26

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Clinical Research, Inc.

    Banning, California

  • Northern California Research

    Sacramento, California

  • Syrentis Clinical Research

    Santa Ana, California

  • Meridien Research

    Lakeland, Florida

  • Meridien - Maitland

    Maitland, Florida

  • The Neurology Research Group

    Miami, Florida

  • Accelerated Enrollment Solutions (AES)

    Orlando, Florida

  • IMIC, Inc

    Palmetto Bay, Florida

  • Meridien Research - Spring Hill

    Spring Hill, Florida

  • Meridien Research - St Petersburg

    St. Petersburg, Florida

  • Meridien Research - Tampa

    Tampa, Florida

  • NeuroStudies, LLC

    Decatur, Georgia

  • Advanced Clinical Research

    Meridian, Idaho

  • Wake Research - CRCNV

    Las Vegas, Nevada

  • Rapid Medical Research

    Beachwood, Ohio

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Palmetto Clinical Research

    Summerville, South Carolina

  • Advanced Clinical Research - Cedar Park

    Cedar Park, Texas

  • FMC Science

    Lampasas, Texas

  • Advanced Clinical Research, Inc.

    West Jordan, Utah

  • Kingfisher Cooperative, LLC

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.